Featured Research

from universities, journals, and other organizations

New possibilities for prostate cancer treatment revealed

Date:
May 29, 2013
Source:
Monash University
Summary:
Researchers have identified a sub-group of cells that could contribute to prostate cancer recurrence, opening up new ways to treat the disease.

Researchers have identified a sub-group of cells that could contribute to prostate cancer recurrence, opening up new ways to treat the disease, which claims more than 3000 lives a year in Australia.

Published today in Science Translational Medicine, a study led by Monash University researchers has found prostate cancer cells that survive androgen withdrawal treatment. Previously unidentified, these cells are potential targets for future treatments. As they are present early in disease development, there is the possibility of therapy before the cancer reaches the aggressive, incurable stage.

Prostate cancer is the most common form of cancer in men, with around 20,000 new cases diagnosed each year in Australia.

For advanced cases, the best available treatment involves drugs that effectively mimic castration and so deprive the tumour of the male hormones that cause it to grow. Androgen deprivation therapy is highly effective; however, the tumour eventually becomes resistant to the treatment and regrows in an incurable form.

Led by Professor Gail Risbridger and Dr Renea Taylor of Monash University, researchers obtained tumour samples from 12 men with early stage, localised prostate cancer. Then, using mouse models to mimic the progression in humans, they closely observed how the cancer cells responded to and survived androgen deprivation therapy. Even after several weeks of androgen deprivation, residual tumour cells continued to persist.

"The results indicate that these persistent cancer cells somehow differ from cancer cells that respond to androgen withdrawal, and are likely to be the precursor cells that lead to advanced androgen-resistant disease. We will now investigate how to effectively target these cells," Professor Risbridger said.

Professor Mark Frydenberg of the Monash Department of Surgery, and Chairman of the Department of Urology, Monash Health, said ultimately the findings could lead to additional therapies to increase the effectiveness of existing prostate cancer treatments.

"This new information suggests that potentially some of the powerful targeted therapies now being used for advanced prostate cancer may have a role to play in earlier localised cancers, especially those with high-risk features, and this hypothesis can be actively tested," Professor Frydenberg said.

"It also allows for testing of novel new compounds to determine if these agents have effectiveness against these hormone resistant cells."

The research was supported by the National Health and Medical Research Council of Australia, the Victorian Cancer Agency and the Prostate Cancer Foundation of Australia.


Story Source:

The above story is based on materials provided by Monash University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Roxanne Toivanen, Mark Frydenberg, Declan Murphy, John Pedersen, Andrew Ryan, David Pook, David M. Berman, Australian Prostate Cancer BioResource, Renea A. Taylor, and Gail P. Risbridger. A Preclinical Xenograft Model Identifies Castration-Tolerant Cancer-Repopulating Cells in Localized Prostate Tumors. Science Translational Medicine, 2013; 2013: 5 (187): 187ra71 DOI: 10.1126/scitranslmed.3005688

Cite This Page:

Monash University. "New possibilities for prostate cancer treatment revealed." ScienceDaily. ScienceDaily, 29 May 2013. <www.sciencedaily.com/releases/2013/05/130529144315.htm>.
Monash University. (2013, May 29). New possibilities for prostate cancer treatment revealed. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/05/130529144315.htm
Monash University. "New possibilities for prostate cancer treatment revealed." ScienceDaily. www.sciencedaily.com/releases/2013/05/130529144315.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins